Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia
Christopher Wård, Robert K. Andrews, Stefano Barco, Elisabeth M. Battinelli, Éric Boilard, Mettine H.A. Bos, Gaëtan Chicanne, Ampaiwan Chuansumrit, Edward M. Conway, Nicola Curry, Daniel F. Cutler, Elisa Danese, Simon F. De Meyer, Jose Mauricio Del Rio, Jenny M. Despotovic, Jorge Di Paola, John W. Eikelboom, Jonas Emsley, Koji Eto, Karin Fijnvandraat, Robert Flaumenhaft, Matthew J. Flick, Tobias A. Fuchs, Keith Gomez, Shinya Goto, Justin R. Hamilton, Ian S. Hitchcock, Craig N. Jenne, Jill M. Johnsen, Lining Arnold Ju, Grégoire Le Gal, M Levade, Professor Gregory Lip, Jim Luyendyk, Coen Maas, Maria K. Magnusson, Pierre Mangin, Alan E. Mast, Claire McLintock, S. Miranda, Amit Nathwani, Heyu Ni, Fionnuala Ní Áinle, Susie Nilsson, Tor Ny, Sarah H. O’Brien, James S. O’Donnell, Bernard Payrastre, Peter Karlheinz, Janusz Rak, Anna M. Randi, Lubica Rauova, Christoph Reinhardt, Marc Rodger, Matthew T. Rondina, Karen Schreiber, Sonia Séverin, Midori Shima, Alex C. Spyropoulos, Simon Stanworth, Katsue Suzuki‐Inoue, Moumneh Thomas, Nagaharu Tsukiji, Tetsumei Urano, Carl Valet, Karen Vanhoorelbeke, Peter Verhamme, Jeffrey I. Weitz, Alisa S. Wolberg, Dominica Zentner, Cheng Zhu (2019). Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. , 3(3), DOI: https://doi.org/10.1002/rth2.12225.
Article25 days agoPOSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). POSTER: MM-1484 DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01370-9.
Article24 days agoMM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Meletios A Dimopoulos, Claudio Cerchione, Nick Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opa, Vânia Hungria (2025). MM-1484: DREAMM-7 Study of Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Features. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02741-7.
Article24 days agoCharacterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
Paweł Robak, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Sebastian Grosicki, Kristin Morris, Maureen Nichols, Benga Kazeem, Elisabet E. Manasanch, Lydia Eccersley, Meral Beksaç, Meletios A Dimopoulos (2025). Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03965-5.
Article24 days agoBelantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Martínez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E. Gatt, Albert Oriol Rocafiguera, Michèle Cavo, Robert M. Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Shing Yip Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalińska, María-Victoria Mateos (2025). Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. , 26(8), DOI: https://doi.org/10.1016/s1470-2045(25)00330-4.
Article24 days ago